The Secretary of State for Health (Dr. John Reid): With permission, Mr. Speaker, I wish to make a statement about a blood transfusion incident involving variant Creutzfeldt-Jakob disease, better known as vCJD. It might assist the House if I begin by setting out the basic facts, before coming on to discuss the implications of the incident that I shall describe.
In March 1996, a blood donor, who was at the time free of signs of vCJD, donated blood to the National Blood Service. Shortly after this, the donated blood was transfused into a patient who underwent surgery for a serious illness. In continuing my description of these events, I will refer to the individuals as the donor and the recipient. The donor showed no signs of vCJD at the time when blood was given, but developed the disease three years laterin 1999and died from it. The recipient died in the autumn of this year. Initial post-mortem examination of the recipient showed changes in the brain indicative of CJD. Further examinations and tests of the patient's brain confirmed the diagnosis of variant CJD. The link between the donor and the recipient was first reported to officials in my Department on 9 December 2003, at which time the diagnosis of vCJD in the recipient was still being confirmed.
I was first alerted to the developments on Friday 12 December, and was briefed by the chief medical officer on Monday and Tuesday of this week. Today, I am bringing this information to the House at the earliest opportunity. I have given, and will give, minimal personal and clinical details of the recipient, because the family concerned wish to have their privacy respected.
In the light of the facts that I have outlined, it is therefore possible that the disease was transmitted from donor to recipient by blood transfusion, that the blood of the donor was infectious three years before the donor developed vCJD, and that the recipient developed vCJD after a six-and-a-half-year incubation period. This is a possibility, not a proven causal connection, because it is also possible that both individuals separately acquired vCJD by eating bovine spongiform encephalopathy-infected meat or meat products. This is a single incident, so the possibility of the infection being transfusion-related cannot be discounted, although it is impossible to be sure what the exact route of infection was. That is the conclusion of the chief medical officer and the experts who report to me.
It is because this is the first report from anywhere in the world of the possible transmission of variant CJD from person to person via blood that I thought it right to come to the Dispatch Box and inform the House, even if only on a precautionary basis.
The incident was discovered by good surveillance. In 1997 the Department of Health funded a research study, the transfusion medicine epidemiology reviewTMERstudy, to examine links between all the variant CJD cases and any form of blood transfusion. It is through that research study that the association between those two patients was identified. I should also point out that this emphasises the importance of post-mortem examination. Without it we would never have
I can inform the House that, as some will already know, there is as yet no blood test for variant CJDor, for that matter, for BSElet alone one that could detect the disease years before symptoms develop, so there is no way of screening blood donations for the presence of the CJD group of diseases. Fortunately, however, a range of precautionary measures have been put in place by the Government since 1997, even though there was at that time no evidence of the risk of person-to-person transmission of the disease via blood. For the benefit and reassurance of the House, I think it right to set out the action that has been taken to date and the further action that we now propose.
First, since 1997 all cases of variant CJD reported to the national CJD surveillance unit and diagnosed as having "probable" variant CJD result in a search of the National Blood Service blood donor records. If the patient has given blood, any stocks of that blood are immediately destroyed.
Secondly, on 17 July 1998, acting on expert advice, the Government announced a £70 million programme to remove most of the white cells from blood destined for transfusion. White cells were considered by experts to be a potential source of infection. This process of so-called leuco-depletion was then a highly precautionary measure to reduce what was then a hypothetical source of infectivity. The process of leuco-depletionthe removal of the white blood cellswas implemented by the National Blood Service over time, and completed by October 1999.
Thirdly, in November 1998, again acting on expert committee advice, the Government announced a £30 million programme to phase out the use of United Kingdom-sourced plasma in the manufacture of blood products. At the time, in the absence of any defined risks, that was another highly precautionary measure. From the end of 1999, therefore, all blood products have been made using plasma sourced from the United States of America. To ensure continuity of supply, the Department of Health purchased on 17 December 2002 the largest remaining independent US plasma collector, Life Resources Incorporated, as part of our attempt to ensure that plasma and plasma-related products were derived from sources outside the United Kingdom.
Fourthly, the National Blood Service has informed us that 15 people received donations of blood from donors who subsequently developed variant CJD. Of the 15 individuals, we have been informed that five received blood after leuco-depletion had been implemented, and the remainder before. The earliest of those 15 transfusions was in 1993 and the latest in 2001. Working with the National Blood Service, the Health Protection Agency is in the process of contacting those individuals. All will be told about the circumstances of their case and have the opportunity to discuss the risks with an expert counsellor.
Fifthly, before these events, expert groups were already deliberating on whether further measures were required in relation to vCJD and blood. In October this year our expert Advisory Committee on the Microbiological Safety of Blood and Tissues for Transplantation advised, on the basis of a risk assessment, that further action, such as stopping people who have received a blood transfusion giving blood, was not necessary. However, in the light of today's statement, we have asked that committee to look comprehensively at whether further precautionary measures could be taken that would not adversely impact on the safety or availability of blood.
Sixthly, it is apparent that much more blood and blood products are used clinically than need to be used. There have been many past attempts to reduce the use of blood to situations where it is absolutely needed medically, but these have been only partially successful. I will therefore be asking the National Blood Service to have urgent discussions with the medical royal colleges and NHS hospitals to address that area of clinical practice. More appropriate blood usage will reduce all the risks associated with blood and will make more effective use of our precious blood supplies.
A finding of this kind, albeit one whose full medical significance is still far from clear, will inevitably give rise to concern. It is therefore important to take account of the wider context in two respects. First, since the events in 1996, approximately 24 million units of blood or blood components have been given to patients in the United Kingdom. Blood transfusion can be a life-saving treatment, but no medical treatment is free from all risks. Indeed, it is an unfortunate fact that already approximately 12 people die each year from complications of blood transfusion. Many people receiving blood transfusion are already very ill, some in life and death situations. A wide range of measures are routinely used to reduce the risks of transfusion by screening for HIV/AIDS, hepatitis B and C and other infections. For specific high-risk patients, even more detailed screening takes place.
Those wider measures should be seen in the context of the precautionary action already taken on vCJD and the recognition that so far we have only one single report of a possible link between a single donor and a single recipient. We are generally regarded internationally as having a very safe blood service, especially because of our precautionary approach to screening for infection, careful donor selection and the tradition of volunteering in this country, which means that our donors generally have a lower incidence of many viral diseases compared with those in other countries who are paid for their donations.
Finally, as to the wider situation for vCJD, we have thankfully not so far seen the thousands of cases of vCJD that some projections suggested. As of 1 December 2003, there had been a cumulative total of 143 cases of vCJD in the United Kingdom. Over the past three years, the annual number of new cases has fallen each year. However, there should be no complacency, as it remains premature to conclude that the epidemic has peaked, and in any case, any single case of vCJD is tragic for the patients and families concerned.
I hope that my statement has given the House a clear and accurate account of the finding in the full context in which it needs to be seen. I have asked the chief medical officer to oversee the further work and investigation required, and to keep me closely informed. I will, of course, also keep the House informed of any major developments in this area.